DSGN
Design Therapeutics Inc
NASDAQ: DSGN · HEALTHCARE · BIOTECHNOLOGY
$15.79
-1.02% today
Updated 2026-06-05
Market cap
$745.11M
P/E ratio
—
P/S ratio
29,402.82x
EPS (TTM)
$-1.20
Dividend yield
—
52W range
$3 – $17
Volume
0.8M
Design Therapeutics Inc (DSGN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-31.97%
ROA
-20.90%
Debt/equity
0.01x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $834000.00 | $-2.05M | -0.10% | -228.78% | -245.44% |
| 2020 | $226.00 | $-8.28M | -2,212.39% | -3,785,840.71% | -3,663,716.81% |
| 2021 | $0.00 | $-35.53M | — | — | — |
| 2022 | $0.00 | $-58.62M | — | — | — |
| 2023 | $0.00 | $-66.86M | — | — | — |
| 2024 | $0.00 | $-49.59M | — | — | — |
| 2025 | $0.00 | $-69.79M | — | — | — |
Frequently asked questions
What is Design Therapeutics Inc's revenue?
Design Therapeutics Inc's trailing twelve-month revenue is $33000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does DSGN generate?
DSGN produced $-54.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is DSGN's balance sheet healthy?
DSGN holds $16.86M in cash and equivalents against — in long-term debt, on $212.50M of shareholder equity. That debt is best read against the cash flow the business throws off each year.